HNN3.0
Register
Register
Register

Project cooperationUpdated on 23 January 2026

Neuromodulation wearable platform for neurodegeneration.

CEO at NEUROCIA

Toulouse, France

About

Neurocia is developing a non‑invasive multimodal neuromodulation platform and wearable device called NeuroPod®, which combines radiofrequency (RF), photobiomodulation and gamma‑frequency entrainment to slow Alzheimer’s disease and related neurodegenerative disorders.

Neurocia has in‑house RF neuromodulation platform technology and dedicated development and manufacturing capabilities, including an R&D and manufacturing site in Serbia.

Neurocia will coordinate device/platform development, system integration and regulatory/risk‑management work packages, and are seeking clinical sites, academic groups (biomarkers, neuroimaging, digital outcomes) and industrial partners (clinical trials, data/AI, large‑scale manufacturing) for a Horizon Europe IND‑03 proposal. 

The goal is to co‑develop and clinically validate a home‑usable neuromodulation wearable to improve quality of life, generating evidence on safety, efficacy, biomarkers and patient adherence.

Topic

  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Type

  • Consortium/Coordinator seeks Partners
  • Partner seeks Consortium/Coordinator

Organisation

NEUROCIA

Start-up

Toulouse, France

Similar opportunities

  • Project cooperation

    Therapeutic Methods to Reduce Disability After Brain Injury (Ischemic Stroke)

    Burcu Talu

    Professor at Inonu University

    Malatya, Türkiye

  • Project cooperation

    Neuromodulation in Rehabilitation

    • Partner seeks Consortium/Coordinator
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Eugen Romulus Lontis

    Associate Professor at Aalborg University Hospital, Region North Denmark

    Aalborg, Denmark

  • Project cooperation

    Medical device industry partner

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Daniel Canavan

    R&D Engineer at Boston Scientific

    Clonmel, Ireland